SCHEMBL2962688

SCHEMBL2962688

Nc1ncnc2c1c(-c1ccc3c(ccn3Cc3ccccc3F)c1)nn2-c1ccc(CN2CCOCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 7/20 0.44
▸ BTK Q06187 2/20 0.41
▸ SRC P12931 4/20 0.41
▸ PIK3C2B O00750 2/20 0.41
▸ PIK3CG P48736 4/20 0.41
▸ PIK3CD O00329 2/20 0.41
▸ PIK3CA P42336 2/20 0.41
▸ PIK3CB P42338 2/20 0.41
▸ PRKDC P78527 2/20 0.41
▸ EGFR P00533 3/20 0.40
▸ STAT6 P42226 1/20 0.40
▸ LCK P06239 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ RET P07949 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ KIT P10721 1/20 0.39
▸ PDGFRA P16234 1/20 0.39
▸ CDK11B P21127 1/20 0.39
▸ CCNC P24863 1/20 0.39
▸ FLT4 P35916 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960418 0.81 IGF1R (0.66) IGF1REGFRRETERBB2KDR
SCHEMBL2960420 0.81 IGF1R (0.66) IGF1REGFRRETERBB2KDR
SCHEMBL2965844 0.79 EGFR (0.48) IGF1RSRCPIK3CGPIK3CDPIK3CA
SCHEMBL2959636 0.75 IGF1R (0.67) IGF1REGFRERBB2
SCHEMBL2959638 0.75 IGF1R (0.67) IGF1REGFRERBB2
SCHEMBL2962189 0.75 IGF1R (0.60) IGF1REGFRERBB2
SCHEMBL2959561 0.74 IGF1R (0.61) IGF1REGFRERBB2
SCHEMBL2968808 0.74 IGF1R (0.60) IGF1REGFRERBB2
SCHEMBL2953983 0.73 IGF1R (0.66) IGF1REGFRRETERBB2KDR
SCHEMBL2953982 0.73 IGF1R (0.66) IGF1REGFRRETERBB2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 IGF1R 1941/4885BTK 380/4885SRC 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback